Bruker launches advanced 3D X-ray microscope

KONTICH, Belgium - Bruker Corporation (NASDAQ:BRKR), a $7.37 billion scientific instruments manufacturer currently trading near its 52-week low of $48.36, has introduced the X4 POSEIDON, a new benchtop 3D X-ray microscope (XRM) system, which promises to deliver high-resolution imaging capabilities comparable to those of larger, floor-standing systems. According to InvestingPro data, the company has maintained strong revenue growth of 13.56% over the last twelve months. The X4 POSEIDON is designed to support a wide range of XRM applications in both industrial settings and scientific research, with features that aim to make sophisticated 3D X-ray microscopy more accessible.

The system boasts a high-end X-ray source that significantly improves 3D resolution, surpassing similar instruments by more than an order of magnitude. It also includes a large field-of-view high-efficiency detector and offers the option to combine this with a high-resolution scientific CMOS detector, thereby providing multi-vision analytical flexibility.

To complement its hardware, the X4 POSEIDON is equipped with 3DxSUITE software, which features automated protocols, a customizable user interface, integrated database and user management, and multi-language support. The system is designed for low maintenance, enhancing uptime and reducing the total cost of ownership. Additionally, field-upgradable options allow users to expand the system’s capabilities in a cost-effective manner as analytical needs evolve.

Diederik Ellerbroek, Bruker AXS Vice President for Materials Science XRM, highlighted the X4 POSEIDON’s versatility and performance, noting its suitability for applications in geosciences, pharmaceutical research and quality assurance, composite materials, batteries, renewable energy, and microelectronics. Guillaume Tetard, Bruker Biospin Vice President for Optical and mCT Preclinical Imaging, emphasized the system’s unmatched image quality in its category, making it ideal for life-science applications, including bone and dental research, soft tissue imaging, and biological studies of plants and animals.

Bruker Corporation, a leader in the post-genomic era, is known for providing high-performance scientific instruments and analytical and diagnostic solutions that support breakthrough discoveries and applications to improve human life quality. The company maintains a healthy gross profit margin of 50% and demonstrates solid financial health, as indicated by its current ratio of 1.6. InvestingPro analysis reveals 8 additional key insights about Bruker’s financial position, available to subscribers. The company’s products are instrumental in a wide array of research and industrial fields, including life science molecular and cell biology research, applied and biopharma applications, microscopy and nanoanalysis, industrial and cleantech research, and semiconductor metrology.

This announcement is based on a press release statement from Bruker Corporation. While trading at a relatively high P/E ratio of 63.9x, InvestingPro’s Fair Value analysis suggests the stock may be slightly undervalued at current levels. For deeper insights into Bruker’s valuation and growth prospects, investors can access the comprehensive Pro Research Report, part of the extensive analysis available for over 1,400 US stocks on InvestingPro.

In other recent news, Bruker Corporation reported its fourth-quarter 2024 earnings, surpassing analysts’ expectations with an earnings per share (EPS) of $0.76, compared to the forecast of $0.74. The company also exceeded revenue projections, reporting $979.6 million against the expected $962.38 million, marking a 14.6% year-over-year increase in quarterly revenue. Additionally, Bruker announced significant advancements in proteomics technology at the 21st Annual US HUPO Conference, including the introduction of the Athena Ion Processor and updates to its software platforms, enhancing the study of complex biological processes.

Bruker also recently appointed Laura Francis as an independent director to its board, with plans for her to join the Audit Committee as a financial expert. Francis brings extensive experience from her roles in various companies, including SI-BONE, Inc. These developments reflect Bruker’s ongoing commitment to innovation and strategic growth.

Furthermore, Bruker’s recent earnings call highlighted the company’s focus on strategic acquisitions and product innovations, which have bolstered its competitive position in key markets. The company’s guidance for 2025 indicates expected revenue growth and margin expansion, with projected revenue between $3.47 billion and $3.54 billion. Analyst firm feedback suggests confidence in Bruker’s strategic direction, with expectations of continued growth and market demand for its products.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.